Home Navidea Biopharmaceuticals Inc (NAVB) Upgraded to "Buy" by Zacks Investment Research
 

Keywords :   


Navidea Biopharmaceuticals Inc (NAVB) Upgraded to "Buy" by Zacks Investment Research

2016-04-09 14:25:16| Biotech - Topix.net

The firm presently has a $1.25 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target suggests a potential upside of 9.65% from the company's previous close.

Tags: buy research investment upgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.11
24.113DSLL
24.11
24.11
24.11
24.11logicool flight switch panel
24.11Z
24.11 126
More »